School of Medicine, Oregon Health & Science University, Portland, OR, USA.
Pituitary Center, Oregon Health & Science University, Portland, OR, USA.
J Clin Endocrinol Metab. 2022 Feb 17;107(3):e1231-e1241. doi: 10.1210/clinem/dgab748.
Characterization of the clinical features and natural history of nonfunctioning pituitary microadenomas (NFPmAs) is limited by heterogeneous and small-scale studies.
To characterize the clinical presentation and natural history of NFPmAs and evaluate if imaging follow-up interval can be extended.
Retrospective single-center cohort study (years 2006-2021) of conservatively managed patients with NFPmAs. Initial symptoms, pituitary function, and tumor size were assessed. A change in NFPmA size ≥2 mm, as determined by pituitary or brain magnetic resonance imaging (MRI), was considered significant.
There were 347 patients in the study cohort. Headache (78.4%) and fatigue (70.0%) were commonly reported despite no evidence of mass effect or significant pituitary hypofunction. Pituitary deficiencies at baseline were rare, with hypogonadism being most common (5.1%). During a median imaging follow-up period of 29 months (range 3-154), 8.1% of NFPmAs grew. Growth incidence was 2.1 per 100 person-years with a mean and median time to growth of 38.1 (SD ± 36.4) and 24.5 (interquartile range 12.0-70.8) months, respectively. Tumor growth was mild and not associated with new pituitary deficiencies or visual deficits.
These data indicate that the natural history of NFPmAs is overall benign. Consequently, we propose that the initial MRI follow-up timeline for NFPmAs can be extended up to 3 years unless a lesion is close to the optic chiasm, there are worrisome mass effect symptoms, or new pituitary deficiencies.
非功能性垂体微腺瘤(NFPmAs)的临床特征和自然病程的描述受到异质性和小规模研究的限制。
描述 NFPmAs 的临床表现和自然病程,并评估是否可以延长影像学随访间隔。
这是一项回顾性单中心队列研究(2006 年至 2021 年),纳入了接受保守治疗的 NFPmAs 患者。评估了患者的初始症状、垂体功能和肿瘤大小。垂体或脑磁共振成像(MRI)显示肿瘤大小增加≥2mm 被认为有显著变化。
研究队列中有 347 例患者。尽管没有证据表明存在肿块效应或明显的垂体功能减退,但头痛(78.4%)和疲劳(70.0%)是常见的初始症状。基线时垂体功能减退罕见,最常见的是性腺功能减退(5.1%)。在中位数为 29 个月(范围 3-154 个月)的影像学随访期间,8.1%的 NFPmAs 生长。生长发生率为每 100 人年 2.1 例,生长的平均和中位时间分别为 38.1(SD±36.4)和 24.5(四分位距 12.0-70.8)个月。肿瘤生长是轻微的,与新的垂体功能减退或视觉缺陷无关。
这些数据表明,NFPmAs 的自然病程总体上是良性的。因此,我们建议,除非病变接近视交叉、有令人担忧的肿块效应症状或出现新的垂体功能减退,否则 NFPmAs 的初始 MRI 随访时间可以延长至 3 年。